NCT02456714View on ClinicalTrials.gov

Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

October 1, 2018

Study Completion Date

December 1, 2018

Conditions
Cholangiocarcinoma
Interventions
DRUG

FOLFIRINOX

Trial Locations (1)

1105AZ

Academic medical center Amsterdam, Amsterdam

All Listed Sponsors
lead

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

OTHER

NCT02456714 - Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma | Biotech Hunter | Biotech Hunter